share_log

TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma

TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma

TCR2治疗公司在卵巢癌和间皮瘤的额外治疗后股价上涨
Benzinga Real-time News ·  2022/09/28 08:08
  • TCR2 Therapeutics Inc (NASDAQ:TCRR) has announced topline results from the Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors.
  • Gavo-cel demonstrated a disease control rate (DCR) of 77%. 28 of the 30 (93%) patients evaluable for efficacy experienced tumor regression of their target lesions, ranging in magnitude from 4% to 80%.
  • Eight patients experienced target lesion regression greater than 30%, six of whom achieved a partial response (PR).
  • One patient with cholangiocarcinoma was also considered to have achieved a PR, demonstrating that gavo-cel has induced responses in every tumor type tested.
  • The overall response rate (ORR) among patients who received gavo-cel following lymphodepletion chemotherapy was 22% by BICR and 26% by investigator assessment.
  • The median overall survival (OS) for patients with MPM was 11.2 months, whereas the median progression-free survival (PFS) for patients with MPM was 5.6 months.
  • Gavo-cel was generally well tolerated, with a manageable adverse event profile up to DL5.
  • Price Action: TCRR shares are up 9.47% at $1.85 during the premarket session on the last check Wednesday.
  • TCR2治疗公司纳斯达克公司(Temasek Holdings：TCRR)宣布了Gavo-cel 1/2期实体肿瘤试验的1期临床试验的TOPLINE结果。
  • Gavo-cel疾病控制率(DCR)为77%。在可评估疗效的30名患者中，有28名(93%)的靶病变肿瘤消退，幅度从4%到80%不等。
  • 8例靶病变消退超过30%，其中6例部分缓解(PR)。
  • 一名胆管细胞癌患者也被认为获得了PR，这表明Gavo-cel在所测试的每一种肿瘤类型中都有诱导反应。
  • 在淋巴清除化疗后接受Gavocel治疗的患者中，BICR的总有效率(ORR)为22%，研究人员评估的总有效率(ORR)为26%。
  • 中位总生存期(OS)为11.2个月，中位无进展生存期(PFS)为5.6个月。
  • Gavo-cel总体耐受性良好，不良事件发生率可达DL5。
  • 价格行动：周三收盘前，TCRR股价上涨9.47%，至1.85美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发